Inflammatory markers in clinical practice.
Wilson
N
N
Department of Paediatrics, Royal Brompton Hospital, London, United Kingdom. n.wilson@rbh.nthames.nhs.uk
Pedersen
S
S
D000328:Adult; D000367:Age Factors; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001249:Asthma / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D015415:Biomarkers; D001706:Biopsy; D001798:Blood Proteins / Q000032:analysis*; D001944:Breath Tests; D002648:Child; D002986:Clinical Trials as Topic; D003430:Cross-Sectional Studies; D047091:Eosinophil Granule Proteins; D047208:Eosinophil-Derived Neurotoxin; D004804:Eosinophils; D006801:Humans; D007223:Infant; D007249:Inflammation; D018836:Inflammation Mediators / Q000097:blood*; D008168:Lung / Q000473:pathology; D009569:Nitric Oxide / Q000032:analysis; D011237:Predictive Value of Tests; D011379:Prognosis; D012260:Ribonucleases / Q000032:analysis*; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D015415:Biomarkers; D001798:Blood Proteins; D047091:Eosinophil Granule Proteins; D018836:Inflammation Mediators; D009569:Nitric Oxide; D047208:Eosinophil-Derived Neurotoxin; D012260:Ribonucleases